![]() ![]() ![]() Public concern about these and other unanswered questions has coincided with a significant decrease in use of osteoporosis drugs and a leveling off in what had been a promising decline in the incidence of osteoporotic fractures 4,5. There are uncertainties about which people will benefit or may be harmed if they take the drugs long-term. There is a gap in scientific data about the appropriate long-term use of many osteoporosis drugs. Reports of rare but serious adverse events such as atypical femoral fractures and osteonecrosis (death of cells) of the jaw have raised questions about the safety of osteoporosis drug use, especially in people who use the drugs for more than 3–5 years or who had a low risk of fracture when they began treatment. However, the benefits and risks of longer-term treatment are less clear. BPs are effective for short-term use (up to 3–5 years) by people who are at high risk of fracture. Clinical guidelines by various medical organizations recommend bisphosphonates (BPs) as a first line of treatment for most people who have osteoporosis. Food and Drug Administration has approved several types of drugs to prevent osteoporotic fractures. However, medications may be prescribed to prevent fractures if a person has very low bone mineral density or has experienced a prior fragility fracture. Lifestyle changes-including getting adequate nutrition and regular exercise, quitting tobacco use, limiting alcohol use, and preventing falls-can help reduce a person’s risk of osteoporotic fractures. Department of Health & Human Services’ national health promotion and disease prevention initiative. Reducing osteoporosis prevalence and hip fracture incidence are among the major objectives of Healthy People 2020, the U.S. The social and economic burden of osteoporotic fractures is substantial 3. The condition makes people more susceptible to fractures, which can impair their ability to live independently and even threaten their lives 2. More than 10 million people in the United States have osteoporosis 1, a skeletal disorder that causes bones to become weak and fragile as a result of low bone mass. RFA-AG-22-018 and NOT-AR-21-006 encourage more intensive analysis of the risks and benefits of long-term osteoporosis treatment. New Workshop-Related Funding Opportunities ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |